708 related articles for article (PubMed ID: 33616462)
1. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality.
Que Y; Hu C; Wan K; Hu P; Wang R; Luo J; Li T; Ping R; Hu Q; Sun Y; Wu X; Tu L; Du Y; Chang C; Xu G
Int Rev Immunol; 2022; 41(2):217-230. PubMed ID: 33616462
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
3. The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients.
Hariharan A; Hakeem AR; Radhakrishnan S; Reddy MS; Rela M
Inflammopharmacology; 2021 Feb; 29(1):91-100. PubMed ID: 33159646
[TBL] [Abstract][Full Text] [Related]
4. Human and novel coronavirus infections in children: a review.
Rajapakse N; Dixit D
Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
[TBL] [Abstract][Full Text] [Related]
5. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.
Wang J; Jiang M; Chen X; Montaner LJ
J Leukoc Biol; 2020 Jul; 108(1):17-41. PubMed ID: 32534467
[TBL] [Abstract][Full Text] [Related]
6. COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue.
Yongzhi X
Emerg Microbes Infect; 2021 Dec; 10(1):266-276. PubMed ID: 33522893
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients.
Olbei M; Hautefort I; Modos D; Treveil A; Poletti M; Gul L; Shannon-Lowe CD; Korcsmaros T
Front Immunol; 2021; 12():629193. PubMed ID: 33732251
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 infection: an overview on cytokine storm and related interventions.
Montazersaheb S; Hosseiniyan Khatibi SM; Hejazi MS; Tarhriz V; Farjami A; Ghasemian Sorbeni F; Farahzadi R; Ghasemnejad T
Virol J; 2022 May; 19(1):92. PubMed ID: 35619180
[TBL] [Abstract][Full Text] [Related]
9. Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children.
Cron RQ
Curr Opin Rheumatol; 2022 Sep; 34(5):274-279. PubMed ID: 35791863
[TBL] [Abstract][Full Text] [Related]
10. Current Understanding of Multisystem Inflammatory Syndrome (MIS-C) Following COVID-19 and Its Distinction from Kawasaki Disease.
Bukulmez H
Curr Rheumatol Rep; 2021 Jul; 23(8):58. PubMed ID: 34216296
[TBL] [Abstract][Full Text] [Related]
11. Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation.
Amigues I; Pearlman AH; Patel A; Reid P; Robinson PC; Sinha R; Kim AH; Youngstein T; Jayatilleke A; Konig M
Expert Rev Clin Immunol; 2020 Dec; 16(12):1185-1204. PubMed ID: 33146561
[No Abstract] [Full Text] [Related]
12. Cytokine Storm in COVID-19: Immunopathogenesis and Therapy.
Zanza C; Romenskaya T; Manetti AC; Franceschi F; La Russa R; Bertozzi G; Maiese A; Savioli G; Volonnino G; Longhitano Y
Medicina (Kaunas); 2022 Jan; 58(2):. PubMed ID: 35208467
[TBL] [Abstract][Full Text] [Related]
13. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.
Soy M; Atagündüz P; Atagündüz I; Sucak GT
Rheumatol Int; 2021 Jan; 41(1):7-18. PubMed ID: 32588191
[TBL] [Abstract][Full Text] [Related]
14. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection.
Copaescu A; Smibert O; Gibson A; Phillips EJ; Trubiano JA
J Allergy Clin Immunol; 2020 Sep; 146(3):518-534.e1. PubMed ID: 32896310
[TBL] [Abstract][Full Text] [Related]
15. The amount of cytokine-release defines different shades of Sars-Cov2 infection.
Bindoli S; Felicetti M; Sfriso P; Doria A
Exp Biol Med (Maywood); 2020 Jun; 245(11):970-976. PubMed ID: 32460624
[TBL] [Abstract][Full Text] [Related]
16. Immunological Assessment of Pediatric Multisystem Inflammatory Syndrome Related to Coronavirus Disease 2019.
Grazioli S; Tavaglione F; Torriani G; Wagner N; Rohr M; L'Huillier AG; Leclercq C; Perrin A; Bordessoule A; Beghetti M; Schmid JP; Vavassori S; Perreau M; Eberhardt C; Didierlaurent A; Kaiser L; Eckerle I; Roux-Lombard P; Blanchard-Rohner G
J Pediatric Infect Dis Soc; 2021 Aug; 10(6):706-713. PubMed ID: 33180935
[TBL] [Abstract][Full Text] [Related]
17. Cytokine cascade in Kawasaki disease versus Kawasaki-like syndrome.
Bordea MA; Costache C; Grama A; Florian AI; Lupan I; Samasca G; Deleanu D; Makovicky P; Makovicky P; Rimarova K
Physiol Res; 2022 Mar; 71(1):17-27. PubMed ID: 35043641
[TBL] [Abstract][Full Text] [Related]
18. The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19.
Attiq A; Yao LJ; Afzal S; Khan MA
Int Immunopharmacol; 2021 Dec; 101(Pt B):108255. PubMed ID: 34688149
[TBL] [Abstract][Full Text] [Related]
19. Repurposing of drugs targeting the cytokine storm induced by SARS-CoV-2.
Ng WH; Tang PCH; Mahalingam S; Liu X
Br J Pharmacol; 2023 Jan; 180(2):133-143. PubMed ID: 36394425
[TBL] [Abstract][Full Text] [Related]
20. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
